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AbstrACt
Introduction Periconception obesity is associated with 
a higher risk for adverse perinatal outcomes such as 
gestational diabetes mellitus, preeclampsia, large for 
gestational age, operative delivery and preterm birth. 
Lifestyle interventions during pregnancy have resulted 
in insufficient effects on reducing these perinatal 
complications. A few reasons for this disappointing effect 
can be suggested: (1) the time period during pregnancy 
for improvement of developmental circumstances is too 
short; (2) the periconception period in which complications 
originate is not included; and (3) lifestyle interventions 
may not have been sufficiently multidisciplinary and 
customised. A preconception lifestyle intervention might 
be more effective to reduce perinatal complications. 
Therefore, the aim of the Towards Prepared mums study 
is to evaluate the effect of a lifestyle intervention starting 
prior to conception on lifestyle behaviour change.
Methods and analysis This protocol outlines a non- 
blinded, randomised controlled trial. One hundred and 
twelve women (18–40 years of age) with overweight 
or obesity (body mass index≥25.0 kg/m2) who plan to 
conceive within 1 year will be randomised to either the 
intervention or care as usual group. The intervention 
group will receive a multidisciplinary, customised lifestyle 
intervention stimulating physical activity, a healthy 
diet and smoking cessation, if applicable. The lifestyle 
intervention and monitoring will take place until 12 months 
postpartum. The primary outcome is difference in weight 
in kg from baseline to 6 weeks postpartum. Secondary 
outcomes are gestational weight gain, postpartum weight 
retention, smoking cessation, dietary and physical activity 
habits. Furthermore, exploratory outcomes include 
body composition, cardiometabolic alterations, time to 
pregnancy, need for assisted reproductive technologies, 
perinatal complications of mother and child, and lung 
function of the child. Vaginal and oral swabs, samples of 
faeces, breast milk, placenta and cord blood will be stored 
for evaluation of microbial flora, epigenetic markers and 
breast milk composition. Furthermore, a cost- effectiveness 
analysis will take place.
Ethics and dissemination Ethical approval was 
obtained from the Medical Ethical Committee of 
Maastricht University Medical Centre+ (NL52452.068.15/
METC152026). Knowledge derived from this study will 
be made available by publications in international peer- 
reviewed scientific journals and will be presented at (inter)
national scientific conferences. A dissemination plan for 
regional and national implementation of the intervention is 
developed.
trial registration number  ClinicalTrials. gov 
NCT02703753.
strengths and limitations of this study
 ► This randomised controlled trial is innovative by 
evaluating effects of a lifestyle intervention that 
starts prior to conception and continues until 1 year 
postpartum.
 ► The strength of the intervention is its multidisci-
plinary and personalised approach, taken into ac-
count the wishes, needs and opportunities of the 
women at risk.
 ► This study will collect a broad range of data, in-
cluding longitudinal data regarding mechanisms 
hypothesised to be involved in the intergenerational 
transmission of diseases, which is scarcely studied 
yet and allows the generation of new hypotheses.
 ► Women who are willing to participate in the study 
are potentially more motivated to change their life-
style, also when allocated to the care as usual group.
 ► The sample size calculated to answer the primary 
research question may be relatively small in order 
to achieve sufficient power for the effect evaluation 
of some outcome measurements, which therefore 
should be seen as exploratory.
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Figure 1 This vicious circle illustrates the intergenerational transmission of disease. The Towards Prepared mums (TOP- mums) 
study focuses on lifestyle improvement and the effects of this lifestyle improvement in the period between preconception and 
1 year postpartum as illustrated in the upper part of the circle. The effects of an unhealthy lifestyle in this period can impact 
health of the entire life span: (a) longer time to conception and a higher risk for miscarriage; (b) higher risk for pregnancy 
complications such as gestational diabetes mellitus, gestational hypertension and preeclampsia; (c) unfavourable fetal 
programming by epigenetic processes modulating gene transcription, and by transmission of an unfavourable composition of 
microbial flora from mother to child; (d) higher risk for birth and neonatal complications such as operative delivery, small and 
large for gestational age, preterm birth and admission to the neonatal intensive care unit; (e) higher risk for developing obesity 
and pulmonary diseases such as wheezing and asthmatic disease; (f) higher risk for chronic diseases such as diabetes mellitus 
type 2, cardiovascular diseases and dyslipidaemia; (g) higher premature mortality rate.
IntroduCtIon
Worldwide, the prevalence of chronic diseases such 
as cardiovascular diseases, dyslipidaemia and diabetes 
mellitus is increasing. The rising burden from these 
chronic diseases imposes new challenges for healthcare.1 
Key risk factors in the development of chronic diseases 
are lifestyle habits such as smoking, lack of physical 
activity, unhealthy diet and being overweight. As illus-
trated in figure 1, there is increasing evidence suggesting 
that the detrimental effects of being exposed to a certain 
lifestyle originate from the periconceptional period.2–5 
By tackling its earliest origins, improving preconception 
lifestyle is hypothesised to benefit global public health by 
addressing the increasing problem of chronic diseases.
Overweight and obesity before and during preg-
nancy negatively impact fertility,6–8 pregnancy and birth 
outcomes,4 9 and increase the risk for the development 
of chronic disease for both mother and child.10–12 During 
pregnancy, women who are overweight or obese are at 
increased risk to develop complications such as gesta-
tional hypertension (GH), preeclampsia and gesta-
tional diabetes mellitus (GDM), and are more often in 
need of an emergency caesarean delivery.13 14 In addi-
tion, maternal obesity is associated with a higher risk for 
4300.7802.430. Protected by copyright.
 o
n
 N
ovem
ber 29, 2019 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030236 on 19 November 2019. Downloaded from 
3Timmermans YEG, et al. BMJ Open 2019;9:e030236. doi:10.1136/bmjopen-2019-030236
Open access
adverse perinatal outcomes such as congenital abnormal-
ities, large for gestational age (LGA), and birth trauma as 
consequence of shoulder dystocia.15 16 Besides, neonates 
of women with obesity are more likely to be admitted to 
the neonatal intensive care unit.17 In addition to over-
weight, it is clearly established that maternal smoking 
negatively affects the health of mother and newborn. 
Maternal smoking decreases fertility18 and intrauterine 
exposure to smoking is associated with a higher risk for 
small for gestational age (SGA) and preterm birth.19
The risk of adverse events among offspring can extend 
through adulthood, demonstrating a vicious circle of 
intergenerational transmission of diseases.3 5 20 Several 
studies suggest that intrauterine exposure to an unhealthy 
lifestyle can increase the risk of cardiovascular, meta-
bolic and endocrine disease in adult life by unfavourable 
fetal programming.2 5 Studies in animals indicate that 
epigenetic processes might be an important link between 
maternal lifestyle habits, and the risk for developing 
obesity and chronic diseases in adult offspring. Epigen-
etic processes modulate gene transcription, establishing a 
detrimental epigenome during embryogenesis and early 
development of the fetus.21 Furthermore, recent research 
suggests a role for the microbiota in the intergenerational 
transmission of obesity.22 Bacterial diversity is influenced 
by obesity and gestational weight gain.23 It is hypothesised 
that the transfer of an obesogenic microbial flora from 
mother to child during birth contributes to the intergen-
erational transmission of diseases.24
In an attempt to prevent perinatal complications, 
previous studies investigated the effect of lifestyle 
behaviour modification during pregnancy. Although 
these interventions were successful in limiting gesta-
tional weight gain, they were unsuccessful in reducing 
GDM, preeclampsia and LGA in women with obesity.25 
It could be suggested that starting during pregnancy, 
the time span to achieve sufficient impact on pregnancy 
outcomes might be too short. In addition, most study 
protocols did not include a multidisciplinary and custom-
ised approach and did not take into account the effects 
of lifestyle during the periconception period in which 
perinatal complications often originate. Data from large 
population- based studies have shown that reducing body 
mass index (BMI) from overweight or obesity before the 
first pregnancy to normal weight before the subsequent 
pregnancy decreased the risk of GDM and LGA.26 27 
Therefore, a lifestyle intervention that starts during the 
preconception phase might be promising in reducing 
pregnancy and birth complications and thereby provide a 
more promising start for the future generation.
Aim
The primary aim of this study is to evaluate the impact of 
a preconception lifestyle intervention on weight change 
in women with overweight or obesity and with a child 
wish. Secondary study aims are to evaluate the effect of 
the lifestyle intervention on gestational weight gain, 
postpartum weight retention and lifestyle habits such as 
physical activity, dietary intake and smoking behaviour. In 
addition, we will explore the effects of the intervention 
on cardiometabolic alterations, body composition, time 
to pregnancy, need for assisted reproductive technologies 
(ART) and perinatal complications such as GDM, GH, 
preeclampsia, SGA, LGA and preterm birth, cardiometa-
bolic alterations and lung function of the child. Further-
more, effects on the microbial flora, epigenetics and 
breast milk composition will be evaluated. Finally, a cost- 
effectiveness analysis of the lifestyle intervention will be 
conducted.
MEthods And AnAlysIs
This protocol was developed in accordance with the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) 2013 Statement (see online 
supplement 1: SPIRIT checklist).28
study design
This study is a randomised controlled trial (RCT) in which 
the participants and investigators will not be blinded due 
to pragmatic reasons. Participants will be randomised 
1:1 in either the intervention or ‘care as usual’ group 
using block randomisation, with random block sizes of 
2, 4 or 6. Randomisation will be stratified for overweight 
(BMI 25.0–29.9 kg/m2), obesity (BMI ≥30.0 kg/m2) and 
smoking status. The study will start before conception 
and will continue during pregnancy until 1 year after 
delivery. The lifestyle intervention and follow- up will 
end for women who are not pregnant within 1 year after 
randomisation and in case of a fetal demise between 16 
and 24 weeks of gestational age (considered dropout). In 
case of a miscarriage before 16 weeks of gestational age, 
women will continue their participation in the study in 
order to follow- up a potential second pregnancy. Also for 
these women, the lifestyle intervention and follow- up will 
end when they are not pregnant within 1 year of initial 
randomisation.
After childbirth, both parents will be informed about 
participation of their child in the study both verbally as 
well as by the information letter. Participation of the child 
will only be feasible when both parents sign informed 
consent (see online supplement 2: inform consent form 
child). When women/parents decide to quit participa-
tion, they will be asked to continue completing the cost 
and quality of life questionnaires. This will enable us to 
perform an adequate as possible cost- effectiveness anal-
ysis. A flow chart of these procedures is presented in 
figure 2.
setting and study population
The study will be conducted in the South of Limburg, the 
Netherlands, and is initiated and coordinated by Maas-
tricht UMC+. Women will be eligible to participate in this 
study when meeting the following criteria: planning to 
conceive within 1 year, 18–40 years of age and having a 
BMI ≥25.0 kg/m². Smoking is neither an inclusion nor an 
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Figure 2 Flow chart of study procedures.
exclusion criterion. Only women who are able to read and 
speak Dutch or English will be included. Being treated 
in a fertility clinic is not an exclusion criterion. Women 
will be excluded when pregnant at the moment of rando-
misation. In addition, women will be excluded in case of 
haemodynamic significant heart disease, restrictive lung 
disease, congenital metabolic disease, diabetes type II 
dependent on medication, when intellectually disabled 
according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM5) criteria,29 or when they under-
went bariatric surgery in the past.
recruitment
Multiple recruitment strategies will be used to reach an 
adequate number of potential participants (see sample 
size). Recruitment will take place in the region of Maas-
tricht, South of Limburg, the Netherlands. In 2018, in 
this region, 1400 children were born.30 Gynaecologists, 
midwives, general practitioners and the Dutch youth 
healthcare system (a preventive healthcare system avail-
able for all children aged 0–19 years in the Netherlands) 
will be involved in recruiting women. At Maastricht 
UMC+, women may visit a gynaecologist for ART or may 
visit the preconception outpatient clinic because being 
at risk for developing pregnancy complications. In addi-
tion, women may visit their midwife with regard to the 
‘child- wish consultation’ or their general practitioner for 
removing or discussing their birth control. Women in the 
period between two pregnancies will also visit the Dutch 
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youth healthcare system with their previous child(ren). In 
addition, subjects will be recruited via advertisements in 
local newspapers, magazines and websites for (expecting) 
young mothers, and via targeted social media campaigns 
for women of childbearing age living in the Maastricht 
area. Third, for another (cross- sectional) study (manu-
script in preparation), women of reproductive age in 
the region received a questionnaire in which they would 
indicate whether they would be interested in participa-
tion in the current study. When inclusion criteria for the 
current study are met, these women will be contacted for 
participation.
Sample size
A sample size calculation was conducted for the primary 
outcome measure, defined as the mean difference in body 
weight in kg from baseline to 6 weeks postpartum. In a 
previous study that evaluated the effect of a lifestyle inter-
vention in subfertile women, a mean reduction of 3.4 kg 
resulted in a higher natural conception rate.31 Further-
more, 5%–10% weight reduction was associated with a 
reduction of type 2 diabetes incidence in adults at risk due 
to a BMI ≥24.0 kg/m².32 During pregnancy, lifestyle inter-
ventions resulted in 1.5 kg reduction in gestational weight 
gain.33 In some studies, this weight reduction was associ-
ated with a lower prevalence of preeclampsia.33 Taken into 
account these previous results, we determined a mean 
difference of 5±7 kg between the study groups as clini-
cally relevant. For the sample size calculation, an alpha of 
0.05 (two sided) and a power of 80% are used. Taken into 
account a drop- out rate of 44% (based on drop- out rates 
of other lifestyle interventions (22%),31 34–37 fetal demise 
after 16 weeks of gestation (1%),38 39 and time to preg-
nancy >12 months (21%),7 40 41 a total of 112 subjects will 
be included in the current study.
Procedure
Subjects will be recruited via advertisements in newspa-
pers, social media and via healthcare professionals (eg, 
general practitioners, midwives, gynaecologists). On 
registration, women will be contacted by phone to test for 
eligibility based on inclusion and exclusion criteria, and 
the patient information letter will be provided. One week 
of consideration to participate in the study will follow, 
before a baseline visit will be scheduled and informed 
consent will be obtained (online supplement 3: informed 
consent form). During the baseline visit, height and 
weight will be measured to confirm the inclusion criteria 
of BMI ≥25.0 kg/m². Based on BMI and smoking status, 
subjects will be allocated to either the intervention or care 
as usual group by the online randomisation programme 
ALEA (ALEA Clinical B.V., Abcoude, the Netherlands). 
Study visits will take place at Maastricht UMC+and will 
take place during consultation with the personal lifestyle 
coach in order to minimise time investment. Within the 
scope of this study, health checks will be performed in 
addition to regular clinical practice, which might inci-
dentally reveal aberrant findings. These findings will be 
discussed with the subject’s primary caregiver (eg, general 
practitioner, midwife and/or gynaecologist) who will be 
responsible for adequate follow- up and/or treatment.
Care as usual
Both study groups will receive care as usual. In addition, 
women in the intervention group will receive the lifestyle 
intervention as described below. In the Netherlands, 
usual care for women before pregnancy includes access 
to the general practitioner and child wish consultations 
by a midwife. In addition, ART are part of care as usual 
for subfertile women according to the Dutch infertility 
guidelines.42 Access to ART will remain available during 
study participation. Pregnant women have access to their 
general practitioner and their midwife and/or gynaecol-
ogist. After pregnancy, maternity care in the first week 
postpartum at home will support breast feeding. In addi-
tion, frequent consultations will take place at the youth 
healthcare division and for both mother and child access 
to the general practitioner is ensured. During these three 
periods, healthcare professionals will give lifestyle advices 
(according to national guidelines) when women specifi-
cally request for help regarding this topic or when health-
care professionals have other reasons for providing advice 
(eg, when women have a cardiometabolic risk factor). In 
addition, healthcare professionals are not restricted to 
refer women to additional lifestyle guidance (eg, by a 
dietician or lifestyle coach) when needed. Use of addi-
tional lifestyle guidance in the care as usual group will be 
registered and taken into account in the effect evaluation.
lifestyle intervention
The Towards Prepared mums (TOP- mums) lifestyle 
intervention is a multidisciplinary intervention in which 
physical activity, a healthy diet, and if applicable, smoking 
cessation will be stimulated. The design of the study is 
based on a qualitative study executed by our research 
group to determine the needs and wishes of the women 
in the target population (results not published yet). This 
has resulted in a personalised programme, in which each 
participating woman will be assigned to her own personal 
lifestyle coach, who has a medical background and is 
trained in motivational interviewing.43 44 On a regular 
basis, subjects will meet their coach (online supplement 
4: schedule consultations), who will develop a lifestyle 
programme in concordance with each woman. To this 
end, lifestyle habits will be assessed by a nutritional diary, 
questionnaires and activity tracker at baseline. Based on 
this assessment, goals for improvements will be formu-
lated. Dependent on the personal situation, participants 
may choose which goal to work on first, for which a combi-
nation of supporting programme is available (see below). 
The programme will be offered in the periods before, 
during and after pregnancy, with specific lifestyle advice 
for each phase. This lifestyle intervention is easily acces-
sible, innovative by the adaptive and proactive approach 
and the structured offer of lifestyle guidance.
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Smarter pregnancy
Each woman will be provided with a free subscription to 
the mHealth coaching programme ‘Smarter Pregnancy’ 
(Erasmus MC, University Medical Centre, Rotterdam, the 
Netherlands) that has been shown to improve nutrition 
and other lifestyle behaviours in this target population 
before.45–48 The programme offers personal coaching 
for 26 weeks, which is based on current personal circum-
stances, pregnancy, nutrition and lifestyle status. The 
tailored coaching includes a maximum of three digital 
posts per week, providing advice, seasonal recipes for 
healthy meals and additional questions addressing life-
style behaviour, taking into account pregnancy status.
Psychological guidance
For women who suffer from eating disorders in combina-
tion with overweight or obesity, psychological support can 
help with sustainable improvement of lifestyle. In order to 
determine the appropriate supporting programme that 
meet the wishes and needs of the women, a standardised 
quick- scan on eating habits (see online supplement 5: 
screening eating disorders) will be used. A psychologist 
will assess the results and when an eating disorder is 
suspected, women will meet a psychologist of Co- eur who 
applies the DSM-5 criteria for comfirmation.29 Co- eur is a 
mental healthcare institution specialised in the treatment 
of obesity in combination with eating disorders, in which 
a team of psychologists, dieticians and physiotherapists is 
involved in the treatment programme.49 The cornerstone 
of this programme is targeting both the eating disorder 
and possible underlying psychological comorbidities (eg, 
depression). Moreover, a sustainable change of lifestyle, 
and improvements of social and labour participation will 
be targeted. Cognitive–behavioural therapy, cue expo-
sure and system therapy are techniques that will be used. 
In general, this involves coaching sessions two to three 
times a week, for 4 months.
Dietary guidance
A trained dietician will provide individual dietary advice 
every 1 or 2 months, according to the recommendations 
of the Netherlands Nutrition Centre.50 The main focus is 
targeting a healthy diet by improving dairy, fruit and vege-
table intake, and decreasing the intake of low- nutritional, 
energy- dense foods. During pregnancy, a target for the 
maximum gestational weight gain will be set, according to 
the Institute of Medicine guidelines.51 In the postpartum 
period, dietary advice for both mother and child will be 
provided. Breast feeding will be encouraged by a trained 
lactation consultant. The frequency of dietician appoint-
ments is not fixed and can be adapted to the wishes and 
needs of the women, but a general guideline is provided 
in online supplement 4.
Physical activity
To support weekly physical activity at moderate intensity, 
a physical activity programme conducted by professionals 
trained in physical education will be offered by the sports 
department of the municipality of Maastricht. In the 
preconception period, the physical activity programme 
will focus on improving aerobic capacity, muscle strength-
ening and increasing energy expenditure. The variable 
activities will take place at different times and locations 
to facilitate participation. During pregnancy, sessions 
will be conducted by a physiotherapist who is trained 
in offering a sports programme for pregnant women 
(ZwangerFit). Physical fitness, muscle strengthening, 
coordination and stabilisation, especially for the pelvic 
muscles are hallmark of this training. It is previously 
shown that pregnancy- specific exercises reduce the risk 
of lower back pain, and sick leave because of lumbopelvic 
pain during pregnancy.52 Starting at 6 weeks postpartum, 
up to 9 months postpartum, a paediatric physiotherapist 
will provide individual training sessions with a focus on 
emotional bonding, fun in playing for mother and baby 
and stimulating motor development of the child. These 
sessions will take place in the home environment. In addi-
tion, the paediatric physiotherapist will discuss participa-
tion in other activities such as baby swimming classes or 
baby mindfulness.
Smoking cessation
To target smoking cessation, the personal lifestyle coach 
will apply motivational interviewing techniques to 
support women to quit smoking. If necessary, women can 
be referred to a specialised smoking cessation coach for 
more extensive guidance.
outcomes
To determine the effects of the lifestyle intervention on 
the health of the women and child, anthropometric, 
cardiometabolic, lifestyle habits, perinatal and post-
partum outcomes will be measured and registered. In 
addition, blood, faecal, urine and breast milk samples 
will be collected according to the scheme as presented 
in table 1.
The first step in determining what the effect is of the life-
style intervention proposed in this study is to examine the 
effect of the intervention on lifestyle behaviour change. 
It is assumed that lifestyle behaviour change results in 
weight change which is an objective outcome measure-
ment. Based on the hypothesis that weight change will 
result in cardiometabolic changes, the next step is to 
study whether weight change has influence on secondary 
and exploratory outcomes.
Anthropometric measurements
Body weight will be assessed in underwear with no shoes 
in kg to the nearest 0.1 kg using a medical calibrated 
weight scale (Model 799, seca gmbh & co. kg., Chino, 
USA), at each study visit. Height will be determined by 
a stadiometer (Model 220, seca gmbh & co. kg.) cali-
brated in 0.1 cm intervals. BMI will be calculated as the 
weight in kg divided by height in metres squared. Gesta-
tional weight gain is defined as weight in kg from 6 weeks 
of pregnancy to the last prenatal study visit and will be 
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compared with the Institute of Medicine guidelines.51 
Postpartum weight retention is defined as the difference 
in weight in kg between 6 weeks of gestational age and 6 
months postpartum.
Waist and hip circumferences will be measured with a 
non- elastic tape at the end of a natural breath at midpoint 
between the top of the iliac crest and the lower margin 
of the last palpable rib and at the widest point of the 
hip, respectively, standing on both feet equally with arms 
hanging down. The waist/hip ratio will be calculated. 
Furthermore, the body composition (ie, fat and fat- free 
mass) will be measured at three time points during the 
study using deuterium dilution as described before.53 
During pregnancy, calculations for fat mass and fat- free 
mass will be adjusted for gestational specific fat- free mass 
in which deuterium is distributed as well.54 55
Lifestyle habits
To objectively measure physical activity level, partici-
pants will wear an accelerometer (ActiGraph, model 
wGT3X- BT, Pensacola, Florida, USA) for 7 days. Further-
more, the validated Baecke questionnaire will be used to 
measure work, sport and leisure activities.56 To register 
dietary habits, women will be asked to complete a 7- day 
nutritional diary. In addition, the validated Three Factor 
Eating Questionnaire will be used to assess three aspects 
of eating behaviour: cognitive restraint, disinhibition 
and hunger.57 As a component of the nutritional assess-
ment, serum 25- hydroxyvitamin D will be measured using 
the Immulite-1000 (Siemens Healthcare Diagnostics, 
Erlangen, Germany). Vitamin D insufficiency is defined 
as <50 nmol/L.58 Smoking habits will be assessed by a 
questionnaire focussing on smoking behaviour, quitting 
history, the intention to quit, nicotine dependence and 
self- efficacy. Biochemical verification of tobacco will be 
assessed through the piCObabyTM carbon monoxide (CO) 
monitor (Bedfont Scientific, Harrietsham, Maidstone, 
Kent) by measuring CO in exhaled breath. Long- term use 
of tobacco will be measured by the assessment of cotinin 
in urine.
Cardiometabolic outcomes
Fasting blood samples will be taken at different time 
points before, during and after pregnancy to determine 
blood glucose and insulin levels, lipid profile and liver 
enzymes (table 1). Fasting plasma glucose will be deter-
mined using the Cobas 8000 modular analyser (F. Hoff-
mann- La Roche, Basel, Switzerland) and serum insulin 
concentrations using the Immulite-1000. Accordingly, 
the homeostatic model assessment of insulin resistance 
will be calculated (fasting glucose (mmol/L)*(fasting 
insulin (µU/L)/22.5)).59 All participants will undergo an 
oral glucose tolerance test (OGTT) at baseline, 26 weeks 
of gestational age and 12 months postpartum. Blood 
glucose and insulin concentrations will be measured 
1 and 2 hours after ingestion of 75 g glucose. Fasting 
serum total cholesterol, high- density lipoprotein choles-
terol, low- density lipoprotein cholesterol, triglycerides, 
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free- fatty acids, serum alanine transaminase, aspartate 
transaminase, gamma- glutamyl transferase and alkaline 
phosphatase concentrations will be determined using the 
Cobas 8000 modular analyser.
Cardiovascular alterations will be measured by systolic 
and diastolic blood pressure (SBP and DBP), using a 
validated automatic device (A&D Medical UA- 789XL, 
Saitama, Japan) on the left arm after 5–10 min rest in a 
sitting position for four times, with 1 min rest in between. 
Mean SBP and DBP of the three last measurements will 
be calculated. Although cardiovascular morbidity such as 
a high blood pressure might not be present in women 
participating in the study (yet), a precursor might already 
be present and might play a role in the transmission of 
health risk to the next generation. Since arterial stiffness 
and retinal microvasculature are both established as prog-
nostic parameters for cardiometabolic morbidity,60 61 these 
measurements are included in this study. Arterial stiff-
ness will be assessed by the carotid- femoral and carotid- 
radial pulse wave velocity and Augmentation Index using 
the SphygmoCor device, model EM3 (ArtCor, Sydney, 
Australia). Further, retinal vascular images will be made 
of the right eye using a retina camera (Topcon TRC- NW-
300, Topcon Corporation, Tokyo, Japan). The images will 
be analysed to measure the diameter of the four largest 
retinal arterioles and venules and to calculate the arterio-
venous ratio.
Perinatal outcomes
Time to pregnancy is defined as the period between having 
the explicit wish to become pregnant to the moment of 
conception. The need for ART and the reason for this (eg, 
chronic anovulation, not able to conceive for >12 months 
despite an ovulatory cycle) will be registered. Miscarriage, 
GDM, GH, preeclampsia, intrauterine growth restriction 
(IUGR), operative delivery, induction of labour, preterm 
birth, stillbirth and congenital malformations will be 
registered after verifying medical records. Miscarriage is 
defined as the loss of the fetus before 16 weeks of gesta-
tion. Stillbirth is defined as intrauterine fetal death after 
16 weeks of gestation. GDM, GH, preeclampsia and 
IUGR will be determined according to the guidelines of 
the Dutch Society of Obstetrics and Gynaecology. GDM 
is defined as a diagnosis of hyperglycaemia during preg-
nancy, in a woman without pre- existing diabetes mellitus. 
The Dutch national guideline is in line with the WHO 
guideline on Diagnosis and Classification of Diabetes 
Mellitus, which defined hyperglycaemia as the presence 
of either a fasting plasma glucose ≥7.0 mmol/L or 2 hours 
plasma glucose ≥7.8 mmol/L following a 75 g OGTT.62 63 
GH is defined as SBP of at least 140 mm Hg and/or DBP 
of at least 90 mm Hg after 20 weeks of gestational age.64 
Preeclampsia is defined as GH accompanied by protein-
uria (at least 300 mg protein in a 24 hours urine collec-
tion).64 IUGR is defined as estimated fetal weight <p10, 
abdominal circumference <p10 or a decrease in growth 
of at least 20 percentiles within a minimal time frame 
of 2 weeks.65 Preterm birth is defined as birth before 37 
weeks of gestation and will be subdivided in spontaneous 
(delivery started by primary contractions or spontaneous 
rupture of membranes) and indicated (including the 
performance of a caesarean delivery before onset of 
labour or induction of labour) preterm birth. Perinatal 
outcomes will be derived from hospital birth registries.
Postpartum measurements
Birth weight, Apgar score 1 and 5 min after birth, SGA and 
LGA will be derived from birth registries. SGA and LGA 
are defined as birth weight below the 10th percentile, and 
above the 90th percentile of normal values for gestational 
age and gender, respectively.66 Growth charts from the 
first year of life will be derived from regular youth health-
care visits that are part of the Dutch healthcare system. 
Cord blood samples at birth and plasma at 1 year of age 
will be collected to determine glucose, insulin and lipid 
profile. Infant lung function will be assessed by measure-
ments of Functional Residual Capacity, Lung Clearance 
Index, Tidal Volume and airway resistance using the trem-
oFlo C-100 Airwave Oscillometry System (THORASYS, 
Montreal, QC, Canada) at 6 weeks and 12 months post-
partum, according to international standards.67 Further-
more, feeding practices will be registered in terms of 
formula or (exclusive) breast feeding.
Sample collection
During the past years, it has been indicated that obesity 
is related to microbial dysbiosis.68–71 Notably, studies indi-
cated that during pregnancy, the developing fetal gut is 
primed by the gut microbiota and intestinal permeability 
of the mother, particularly towards the later stages of gesta-
tion.72 73 In addition, a major determinant of the micro-
biota composition of newborns is the mode of delivery. 
Vaginally delivered infants harbour bacterial communi-
ties resembling those of the maternal vagina, whereas the 
gut microbiota of caesarean section delivered infants are 
enriched in maternal skin microbiota.74 75 There are also 
indications that breast milk harbours a specific microbial 
community; however, literature is scarce. Therefore, we 
aim to determine the microbiota composition of mothers 
and children (faecal, oral, vaginal, breast milk) and deter-
mine the role of weight loss herein. In addition, breast 
milk composition/metabolome will be investigated,76 77 
and placenta tissue will be collected for RNA- sequencing 
analysis, histology and epigenetics.
Faeces will be collected at home using the TagHemi 
collection system (TagHemi, Zeijen, The Netherlands), 
and divided over two sterile tubes at home (Sarstedt, 
Nürmbrecht, Germany). Subjects will be instructed to 
freeze their samples immediately after defecation and 
use a cool transport container for transport to the univer-
sity. Within 1 week, participants will take the samples to 
the university for storage at −80°C until further analysis. 
Stool samples will be collected at baseline, which will 
be repeated every 3 months for the scope of the study, 
including each trimester of pregnancy. Child faecal 
samples will be collected at age 6 weeks and 12 months. 
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Vaginal (of the mother) and oral (of mother and child) 
swabs will be stored in transport buffer at −80°C until 
further analysis. Breast milk will be collected and stored as 
reported by Lipkie et al.78 Placental tissue will be collected 
and stored as described before.79 Microbiota profiles will 
be generated. Quantitative DNA methylation analysis will 
be performed to explore epigenetic changes. Regions of 
interest will be determined at the moment analyses will 
be performed, to adhere to the most current literature 
among epigenetic changes.
Cost-effectiveness analysis
Questionnaires will be used to obtain insight in care util-
isation. To determine costs (ie, regarding healthcare, 
patient and family costs, and costs outside the healthcare 
sector), a questionnaire is developed taking into account 
the stage women are in (preconception, pregnant, post-
partum). To generate quality adjusted life years, quality 
of life is measured by the validated five- level version of 
EuroQol- 5D questionnaire.80 81
Incentives
Parking and travel costs will be reimbursed. In order to 
acknowledge women for their efforts, during each study 
period (preconception, pregnancy, postpartum) an 
incentive is included such as a free 3D ultrasound during 
pregnancy.
Public and patient involvement
To increase adherence, women in the target population 
were involved in the overall design of the current study. 
A large group of women of childbearing age was inter-
viewed to identify facilitators and barriers to participate 
in a lifestyle intervention that were incorporated in the 
current protocol. In addition, the intervention for each 
participating woman will be adapted to her personal 
needs, possibilities and social situation. Main results will 
be disseminated to trial participants and they are involved 
in the development of an appropriate method of dissem-
ination. Therefore, participating women have a central 
position in the intervention and are involved in every 
phase of the study.
data management
Data will be collected using electronic case record forms 
(MACRO, Elsevier B.V., Amsterdam, the Netherlands) 
that were adapted to the requirements of the current 
study. By using MACRO, the data collected are according 
to the Findable, Accessible, Interoperable and Reusable 
criteria.82 Data will be securely stored for 15 years.
statistical analysis plan
Data will be analysed using SPSS V.24.0 for Windows (SPSS 
Incorporated). Descriptive statistics will be performed 
for baseline characteristics of the study population. Para-
metric data will be presented as means with SD, and non- 
parametric distributed variables as median with IQRs. 
Since the design is a repeated- measures RCT, linear 
mixed- model techniques based on the intention- to- treat 
principle will be used to analyse the difference between 
intervention and care as usual group with respect to 
primary and secondary outcome measurements. This 
technique corrects for within- subject correlation and 
deals with missing values at random. Survival analysis 
will be used to determine the HR for smoking cessation 
and time to pregnancy. Exploratory, paired sample t- tests 
will be used to test for change in exploratory outcomes. 
Analyses will be adjusted for the stratification factors over-
weight/obesity and smoking status. A p value<0.05 will be 
considered statistically significant.
EthICs And dIssEMInAtIon
This study will be monitored independently by the Clin-
ical Trial Centre Maastricht. All adverse events will be 
registered and reported to the medical ethics committee 
of Maastricht UMC+.
The knowledge derived from this study will be made 
available for the scientific community by publications in 
international peer reviewed scientific journals and will 
be presented at (inter)national scientific conferences. 
Study results will be relevant for both researchers as well 
as for primary care providers (ie, midwives, general prac-
titioners and youth healthcare workers) and secondary 
care providers (ie, gynaecologists, hospital- based 
midwives and paediatricians). Furthermore, study results 
will be presented and discussed with policy- makers and 
the public domain.
The TOP- mums lifestyle intervention makes use of 
existing, regional initiatives (that are financially covered) 
for a sustainable solution for lifestyle improvement. 
Therefore, in case proven to be a successful interven-
tion, the approach of TOP- mums can easily be extended 
to a broader area. A dissemination plan for regional and 
national implementation is developed.
dIsCussIon
The main goal of our RCT is to study the effects of a multi-
disciplinary lifestyle intervention for women who plan to 
conceive, who are at higher risk for perinatal morbidity 
because of overweight or obesity. The TOP- mums study 
is one of the first studies that investigates the effect of 
a multidisciplinary and personalised lifestyle interven-
tion starting in the preconception phase, on different 
behavioural, cardiovascular and perinatal outcomes of 
both mother and child before, during and after preg-
nancy. There is growing evidence that lifestyle- related 
aberrations of maternal metabolic health and placenta 
function occur during the first trimester of pregnancy, 
prior to when most interventions are started.33 83 To foster 
healthy living from conception on, the lifestyle interven-
tion in this study is initiated prior to conception.
Previous research regarding preconception lifestyle 
interventions is limited and the effectiveness of multi-
disciplinary and customised interventions is unclear.84–86 
The majority of existing studies targeted subfertile women 
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undergoing ART and discontinued the intervention once 
women became pregnant. When considering interpreg-
nancy weight change, it has been shown that weight loss 
between pregnancies can reduce the incidence rates of 
perinatal complications.26 This paves the way to execute 
an extensive effect evaluation of the lifestyle intervention 
in the current study. The study will significantly contribute 
to the elaboration of the knowledge on the effects of 
preconception lifestyle guidance on improving health for 
the current and next generations. One of the strengths 
of our study is that the lifestyle intervention is developed 
based on the experiences and wishes of the target group 
itself and is customised to the personal objectives of each 
participant. Another asset of this study is the amount 
of data collected, allowing us to better understand the 
consequences and intermediating factors of lifestyle on 
the health of mother and child.
The current protocol has some limitations. First, most 
subjects might enter the study based on intrinsic moti-
vation to implement lifestyle changes. This might result 
in the search for additional lifestyle guidance, also when 
allocated to the care as usual group, thereby potentially 
diluting the intervention effect. Second, although preg-
nancy can be seen as a ‘teachable moment’, poor adher-
ence and high drop- out rates are frequently reported for 
this type of lifestyle interventions.87 However, based on 
experience of our research group, we expect that the 
design of the current lifestyle intervention, including 
a customised approach and the organisation of activi-
ties in proximity of subject’s home and at different time 
points, will limit drop- out rates.88 It is possible that addi-
tional measurements for data collection might be expe-
rienced as extensive by the participants. However, the 
long- standing experience of our research group with 
other lifestyle interventions89–91 is that participants mostly 
appreciate monitoring of their health, which in addition 
often increases motivation.
To conclude, the current TOP- mums protocol describes 
a personalised lifestyle intervention starting in prepara-
tion of conception, continuing until 1 year after birth. By 
improving lifestyle already in the preconception phase, 
the earliest origins of chronic disease might be tackled, 
thereby disrupting the vicious circle of transferring 
harmful lifestyle influences from generation to gener-
ation. The outcomes of the current multidisciplinary, 
customised lifestyle intervention might provide valuable 
information for public health initiatives to foster a healthy 
start for our next generation.
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